# 510(k) SUMMARY

# JUL 0 3 2013

This 510(k) Summary information is submitted in accordance with the requirements of 21 CFR $\ S 8 0 7 . 9 2$ .

510(k) Number: K123983

# Submitter:

Qualigen, Inc. 2042 Corte Del Nogal, Suite B Carlsbad, CA 92009

Telephone: (760) 918-9165   
Facsimile: (760) 918-9127

Date Prepared: June 27, 2013

# Contact Person:

Mr. Michael Poirier   
Senior Vice President, Chief Technical Officer, Chief Scientific Officer   
Telephone: (760) 918-9165 x227   
Facsimile: (760) 918-9127   
Email: mpoirier@qualigeninc.com

# Device Identification

Trade Names: FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay FastPack $\textsuperscript { \textregistered }$ Vitamin D Calibrator Kit FastPack $\textsuperscript { \textregistered }$ Vitamin D Control Kit FastPack $\textsuperscript { \textregistered }$ Vitamin D Method Verification Kit

Common Names: Vitamin D Assay Vitamin D Calibrator Vitamin D Controls Vitamin D Verifiers

Classification names: System, Test, Vitamin D Calibrator Quality control material (assayed and unassayed)

Revised 5 10(k) Summary of Safety and Effectiveness

# Classifications:

Class II (assay) Class II (calibrators) Class I, reserved (controls) Class I, reserved (verifiers)

Panel: Chemistry (75)

Product Codes: MRG - Vitamin D test system JIT - Calibrator, Secondary JJX - Single (specified) Analyte Controls (Assayed and Unassayed)

Regulation Numbers: 21 CFR § 862.1825 - Vitamin D test system 21 CFR $\ S$ 862.1150 - Calibrator 21 CFR $\ S$ 862.1660 - Quality control material (Assayed and Unassayed)

# Devices to Which Substantial Equivalence is Claimed

LIAISON $\textsuperscript { \textregistered }$ 25 OH Vitamin D TOTAL Assay

DiaSorin Inc.   
1951 Northwestern Avenue PO Box 285   
Stillwater, MN 55082-0285 K112725

# Device Description

The FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay employs a competitive immunoassay principle. Endogenous Vitamin D in a patient sample, calibrator, control, or verifier is mixed with pretreatment buffer then added into a FastPack $\textsuperscript { \textregistered }$ reagent pack. In the reagent pack, the pre-treated Vitamin D sample binds with a monoclonal (mouse) anti-Vitamin D antibody covalently linked to alkaline phosphatase (ALP). After incubation, a conjugate of Vitamin D-Biotin linked to streptavidin coated paramagnetic particles is added. Monoclonal anti-Vitamin D antibody-ALP conjugate not reacted with Vitamin D in the sample will bind to unoccupied binding sites of the Vitamin D-biotin conjugate bound to the streptavidin paramagnetic particles. After washing steps (using a Tris buffer containing detergents) to separate bound from unbound anti-Vitamin D monoclonal antibody-ALP, a chemiluminogenic substrate mixture is added to the system. This mixture contains indoxyl-3-phosphate, a substrate for ALP, and lucigenin $( \mathrm { N } , \mathrm { N } ^ { \gimel } .$ . dimethyl $^ { 9 , 9 ^ { \prime } }$ -biacridinium dinitrate). ALP dephosphorylates indoxyl-3-phosphate to indol-3-ol, which subsequently undergoes oxidation. As a result, lucigenin is reduced to form a dioxetane structure that is cleaved to yield $\mathsf { N }$ -methylacridone. This compound produces a sustained luminescent glow following excitation. The raw relative luminescence units (RLUs) generated are measured by a photomultiplier tube in the FastPack $\textsuperscript { \textregistered }$ Analyzer and are inversely proportional to the concentration of Vitamin D in the sample. The entire reaction sequence takes place at $3 7 \pm 0 . 5 ^ { \circ } \mathrm { C }$ and is protected from external light.

# Intended Use

FastPack $^ \mathrm { \textregistered }$ Vitamin D Immunoassay is intended for the quantitative determination of total 25-hydroxyvitamin D and other hydroxylated metabolites in human serum and plasma. The assay is to be used as an aid in the assessment of vitamin D sufficiency in adults. The FastPack $^ \mathrm { \textregistered }$ Vitamin D Immunoassay is intended for use with the FastPack $^ \mathrm { \textregistered }$ Analyzer.

The FastPack $\textsuperscript { \textregistered }$ Vitamin D Calibrator Kit is used for calibrating the quantitative FastPack $^ { \textregistered }$ Vitamin D Immunoassay on the FastPack $^ \mathrm { \textregistered }$ Analyzer.

FastPack $\textsuperscript { \textregistered }$ Vitamin D Control Kit is used for quality control of the FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay on the FastPack $^ \mathrm { \textregistered }$ Analyzer.

FastPack $\textsuperscript { \textregistered }$ Vitamin D Method Verification Kit is used in the quantitative verification of calibration and assay range of the quantitative FastPack $^ \mathrm { \textregistered }$ Vitamin D Immunoassay on the FastPack $\textsuperscript { \textregistered }$ Analyzer.

# Comparison of new device to predicate devices

Similarities between FastPack® and LIAISON@ Vitamin D Assays   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack® VitaminD Immunoassay</td><td rowspan=1 colspan=1>DiaSorin LIAISON® 25 OHVitamin D TOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>for the in-vitro quantitativedetermination of total 25-hydroxyvitamin D and otherhydroxylated metabolites inhuman serum and plasma. Theassay is to be used as an aid inthe assessment of vitamin Dsufficiency in adults. TheFastPack® Vitamin D Assay isintended for use with theFastPack® Analyzer.</td><td rowspan=1 colspan=1>for the quantitativedetermination of 25-hydroxyvitamin D and otherhydroxylated vitamin Dmetabolites in human serumto be used in the assessmentof vitamin D sufficiency.Assay results should be usedin conjunction with otherclinical or laboratory data toassist the clinician in makingindividual patientmanagement decisions in anadult population.</td></tr></table>

Revised 5 10(k) Summary of Safety and Effectiveness   

<table><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum or plasma (lithium-heparin or EDTA)</td><td colspan="1" rowspan="1">Serum only</td></tr><tr><td colspan="1" rowspan="1">Sample Preparation</td><td colspan="1" rowspan="1">Standard processing for serumor plasma</td><td colspan="1" rowspan="1">Standard processing forserum</td></tr><tr><td colspan="1" rowspan="1">Assay principle</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Chemiluminescence</td></tr><tr><td colspan="1" rowspan="1">Approximate run time</td><td colspan="1" rowspan="1">10 minutes</td><td colspan="1" rowspan="1">20 minutes</td></tr><tr><td colspan="1" rowspan="1">Interpretation ofResults</td><td colspan="1" rowspan="1">Standard Curve</td><td colspan="1" rowspan="1">Standard Curve</td></tr><tr><td colspan="1" rowspan="1">Reagent StorageTemperature</td><td colspan="1" rowspan="1">2-8 °</td><td colspan="1" rowspan="1">2-8 </td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">The FastPack® Vitamin DImmunoassay is a directcompetitive chemiluminescenceimmunoassay employingparamagnetic particles.</td><td colspan="1" rowspan="1">The DiaSorin LIAISON 25OH Vitamin D TOTALAssay is a direct competitivechemiluminescenceimmunoassay employingparamagnetic particles.</td></tr><tr><td colspan="1" rowspan="1">Testing Environment</td><td colspan="1" rowspan="1">Professional use</td><td colspan="1" rowspan="1">Professional use</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within-run: ≤ 15.1Between-run: ≤ 4.9%Total: ≤ 15.1</td><td colspan="1" rowspan="1">Within-run: ≤ 7.7%Between-run: ≤ 3.2%Total: ≤ 12.6%</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">Assay linear from LOQ (12.9ng/mL) to 150 ng/mL</td><td colspan="1" rowspan="1">Assay linear from LOQ (4.0ng/mL) to 150 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Interfering Substances</td><td colspan="1" rowspan="1">No interference from highlevels of bilirubin, hemoglobin,</td><td colspan="1" rowspan="1">No interference from highlevels of bilirubin,</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">cholesterol, lipids, total protein,and biotin</td><td colspan="1" rowspan="1">hemoglobin, triglycerides,uric acid, IgG, albumin, andcholesterol</td></tr><tr><td colspan="1" rowspan="1">Cross-reactivity</td><td colspan="1" rowspan="1">~100% cross-reactivity with25-OH D2, 25-OH D3, and24,25-(OH)2-Vitamin D3;&lt;10% cross-reactivity withVitamin D2, Vitamin D3, 1,25-(OH)2-Vitamin D2, 1,25-(OH)2-Vitamin D3, 3-epi-25(OH) Vitamin D3, 24,25-(OH)2-Vitamin D2, andParicalcitol</td><td colspan="1" rowspan="1">~100% cross-reactivity with25 OH D2, 25 OH D3; &lt;10%cross-reactivity with VitaminD2, Vitamin D3, 3-epi-25OHVitamin D3, 1,25-(OH)2-Vitamin D2, and 1,25-(OH)2-Vitamin D3</td></tr><tr><td colspan="1" rowspan="1">Comparative TestingvSEstablished Methods</td><td colspan="1" rowspan="1">N = 137Range of observations:18.6 to 132.6 ng/mLDeming regression toLIAISON:Slope (95% CI): 0.97 (0.88-1.06)y (95% CI): -4.6 (-8.9 to -0.25)R (95% CI) = 0.92 (0.90-0.94)Sy|x = 10.3</td><td colspan="1" rowspan="1">N= 587Range of observations:4.0 to 150.0 ng/mLLinear regression toradioimmunoassay:Slope (95% CI): 1.047 (1.02-1.07)Y (95% CI): 2.41 (1.43-3.40)R= 0.936</td></tr></table>

Differences between FastPack® and LIAISON® Vitamin D Assays   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Immunoassay</td><td rowspan=1 colspan=1>DiaSorin LIAISON®25 OH Vitamin DTOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>FastPack® Analyzer</td><td rowspan=1 colspan=1>LIAISON® Analyzer</td></tr><tr><td rowspan=1 colspan=1>Assay procedure</td><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Automated</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Internal standards (9 levels) assignedbased on patient correlation withLIAISON® 25 OH Vitamin DTOTAL Assay.</td><td rowspan=1 colspan=1>Standardized using UVquantification of 25-(OH) Vitamin D</td></tr></table>

Similarities between FastPack® and LIAISON® Vitamin D Calibrators   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Calibrator Kit</td><td rowspan=1 colspan=1>DiaSorin LIAISON25 OH Vitamin DTOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationfor Use</td><td rowspan=1 colspan=1>For in-vitro diagnostic use incalibrating FastPack® Vitamin DImmunoassay</td><td rowspan=1 colspan=1>Similar</td></tr><tr><td rowspan=1 colspan=1>Storage temperature</td><td rowspan=1 colspan=1>2-8 </td><td rowspan=1 colspan=1>2-8 °C in the dark</td></tr><tr><td rowspan=1 colspan=1>Matrix•</td><td rowspan=1 colspan=1>Human serum-based matrixcontaining preservative andstabilizers</td><td rowspan=1 colspan=1>Human serum-basedmatrix containingpreservative</td></tr></table>

Differences between FastPack® and LIAISON® Vitamin D Calibrators   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Calibrator Kit</td><td rowspan=1 colspan=1>DiaSorin LIAISON25 OH Vitamin DTOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>Antigen used in calibrators</td><td rowspan=1 colspan=1>No antigen present</td><td rowspan=1 colspan=1>Antigen present</td></tr><tr><td rowspan=1 colspan=1>Number of calibrators</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Open vial stability</td><td rowspan=1 colspan=1>60 days</td><td rowspan=1 colspan=1>4 weeks</td></tr></table>

Similarities between FastPack® and LIAISON® Vitamin D Controls   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Control Kit</td><td rowspan=1 colspan=1>DiaSorin LIAISON® 25 OHVitamin D TOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationfor Use</td><td rowspan=1 colspan=1>For in-vitro diagnostic use tomonitor the precision andaccuracy of the FastPack®Vitamin D Immunoassay onthe FastPack® Analyzer.</td><td rowspan=1 colspan=1>For use as assayed qualitycontrol samples to monitorthe accuracy and precision ofthe DiaSorin LIAISON® 25OH Vitamin D TOTALAssay.</td></tr><tr><td rowspan=1 colspan=1>Antigen used incontrols</td><td rowspan=1 colspan=1>25-(OH) vitamin D</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum-based matrixcontaining preservative andstabilizers</td><td rowspan=1 colspan=1>Human serum-based matrixcontaining preservative</td></tr><tr><td rowspan=1 colspan=1>Number of levels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage temperature</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>Same</td></tr></table>

Differences between FastPack® and LIAISON Vitamin D Controls   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Control Kit</td><td rowspan=1 colspan=1>DiaSorin LIAISON® 25OH Vitamin D TOTALAssay (K112725)</td></tr><tr><td rowspan=1 colspan=1>Open vial stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>No open vial stabilityclaimed</td></tr></table>

Similarities between FastPack $\textsuperscript { \textregistered }$ and LIAISON® Vitamin D Verifiers   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPackVitamin D MethodVerification Kit</td><td rowspan=1 colspan=1>DiaSorin LIAISON® 25 OHVitamin D TOTAL Assay(K112725)</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indication for Use</td><td rowspan=1 colspan=1>For in-vitro diagnostic useto monitor the precisionand accuracy of theFastPack® Vitamin DImmunoassay on theFastPack® Analyzer.</td><td rowspan=1 colspan=1>For use as assayed quality controlmaterials intended for in vitrodiagnostic use in the quantitativeverification of calibration andreportable range of the Liaison 25OH Vitamin D Total Assay whenperformed on the LiaisonAnalyzer.</td></tr><tr><td rowspan=1 colspan=1>Antigen used inVerifiers</td><td rowspan=1 colspan=1>25-(OH) vitamin D</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum-basedmatrix containingpreservative andstabilizers</td><td rowspan=1 colspan=1>Human serum-based matrixcontaining preservative</td></tr><tr><td rowspan=1 colspan=1>Storage temperature</td><td rowspan=1 colspan=1>2-8 °C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Open vial stability</td><td rowspan=1 colspan=1>Single Use - NA</td><td rowspan=1 colspan=1>4 weeks</td></tr></table>

Differences between FastPack® and LIAISON® Vitamin D Verifiers   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTIC</td><td rowspan=1 colspan=1>Qualigen FastPack®Vitamin D Method VerificationKit</td><td rowspan=1 colspan=1>DiaSorin LIAISON® 25OH Vitamin D TOTALAssay (K112725)</td></tr><tr><td rowspan=1 colspan=1>Number of levels</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td></tr></table>

# Performance Summary

# Precision

Precision was evaluated following the CLSI EP5-A2 guidance. Four samples with concentrations of ${ \sim } 2 5$ , ${ \sim } 3 0 , { \sim } 4 5$ , and ${ \sim } 8 0 ~ \mathrm { { n g / m L } }$ were tested in duplicate determinations in each of two runs per day on each of two FastPack $^ \mathrm { \textregistered }$ Analyzers, each paired with an individual FastPack $\textsuperscript { \textregistered }$ Reagent lot over a period of 20 days to yield 160 replicate determinations of each sample (80 replicates per lot/analyzer). Within-run, between-run, and between-day components of variation were calculated as well as total imprecision using a fully nested 2-way random factor ANOVA model with runs nested within days. The tables below present the results by instrument/reagent combination:

Analyzer 1, Reagent Lot 1   

<table><tr><td rowspan=2 colspan=2>Average</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=2 colspan=2>TotalSD    % CV</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=2>SD    % CV</td><td rowspan=1 colspan=2>SD    % CV</td><td rowspan=1 colspan=2>SD    % CV</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>13.4</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>31.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>12.1</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>45.5</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>84.9</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>6.1</td></tr></table>

Analyzer 2, Reagent Lot 2   

<table><tr><td rowspan=2 colspan=2>Average</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=2 colspan=2>Between-DaySD   % CV</td><td rowspan=2 colspan=2>TotalSD   % CV</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=2>SD    % CV</td><td rowspan=1 colspan=2>SD    % CV</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>15.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>15.1</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>32.7</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>12.7</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>46.1</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>76.4</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>4.7</td></tr></table>

# Limits of blank, detection, and quantitation

The Limit of Blank (LOB), the Limit of Detection (LOD), and the Limit of Quantitation (LOQ) of the FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay were determined according to CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation. The following are the limits determined:

$\mathrm { L O B } = 2 . 3 ~ \mathrm { n g / m L }$ $\mathrm { L O D } = 6 . 2 \ : \mathrm { n g / m L }$ $\mathrm { L O Q } = 1 2 . 9 \mathrm { n g / m L }$

# Linearity

Linearity was determined following CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: a Statistical Approach: Approved Guideline. A high patient sample was intermixed with a low sample to generate 9 concentration levels each tested in duplicate determinations. Linear results were compared to $2 ^ { \mathfrak { n } \mathfrak { d } }$ and $3 ^ { \mathrm { { r d } } }$ order polynomial fits against a pre-specified allowable error ${ \mathfrak { o f } } \pm 5 ~ { \mathfrak { n } } { \mathrm { g / m L } }$ .The linearity range was found to extend from the LOQ( $1 2 . 9 \mathrm { n g / m L } )$ to $1 5 0 . 0 ~ \mathrm { { n g / m L } }$ .

# Cross-reactivity

Two samples containing low and high concentrations of Vitamin D were tested without and with added concentrations of potential cross-reacting compounds including 1,25- dihydroxy Vitamin D2; 1,25-dihydroxy Vitamin D3; Vitamin D2; Vitamin D3; 25- hydroxy Vitamin D2; 25-hydroxy Vitamin D3; 24,25-dihydroxy Vitamin D2; 24,25- dihydroxy Vitamin D; 3-epi-25-hydroxy Vitamin D3, and Paricalcitol. Maximum crossreactivity at the indicated cross-reactant concentration tested was determined for each compound.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration(ng/mL)</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Vitamin D2</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Vitamin D3</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>1,25-(OH)2-Vitamin D2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>1,25-(OH)2-Vitamin D3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>9.8</td></tr><tr><td rowspan=1 colspan=1>3-epi-25(OH) Vitamin D3</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>25 (OH) Vitamin D2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.0</td></tr><tr><td rowspan=1 colspan=1>25 (OH) Vitamin D3</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>106.0</td></tr><tr><td rowspan=1 colspan=1>Paricalcitol</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>-1.2</td></tr><tr><td rowspan=1 colspan=1>24, 25 (OH)2 Vitamin D2</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>-0.9</td></tr><tr><td rowspan=1 colspan=1>24, 25 (OH)2 Vitamin D3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>117.4</td></tr></table>

# Interferences

The following substances normally present in blood were tested and found not to interfere in the FastPack $^ \mathrm { \textregistered }$ Vitamin D Immunoassay at the noted concentrations:

Bilirubin Tested to $4 0 \mathrm { m g / d L }$ Biotin Tested to $1 0 0 0 ~ \mathrm { { n g / m L } }$ Cholesterol Tested to $5 0 0 \mathrm { m g / d L }$ EY Total Protein Tested to $1 0 . 7 \ : \mathrm { g / d L }$ Hemoglobin Tested to $5 0 0 \mathrm { m g / d L }$ Lipids Tested to $2 5 0 \mathrm { m g / d L }$

# Serum and plasma equivalence

Blood collections were obtained from 32 volunteers and processed in parallel to serum EDTA plasma, and lithium-heparin plasma. Measurements in FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay were compared via Deming regression and indicated equivalence between the three matrices.

Serum versus EDTA plasma   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>N compared</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Range of observations, ng/mL</td><td rowspan=1 colspan=1>Serum: 17.4 - 139.5Plasma: 14.9 - 134.1</td></tr><tr><td rowspan=1 colspan=1>Absolute bias, ng/mL</td><td rowspan=1 colspan=1>-6.7</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>-11.1</td></tr><tr><td rowspan=1 colspan=2>Regression results</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.993</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>-6.3</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.979</td></tr><tr><td rowspan=1 colspan=1>$R^{2}$</td><td rowspan=1 colspan=1>0.959</td></tr></table>

Serum versus lithium-heparin plasma   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>N compared</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Range of observations, ng/mL</td><td rowspan=1 colspan=1>Serum: 17.4 - 139.5Plasma: 18.1 - 133.3</td></tr><tr><td rowspan=1 colspan=1>Absolute bias, ng/mL</td><td rowspan=1 colspan=1>-2.5</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>-4.1</td></tr><tr><td rowspan=1 colspan=2>Deming regression results</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.970</td></tr><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>-0.7</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.971</td></tr><tr><td rowspan=1 colspan=1>$R^{2}$</td><td rowspan=1 colspan=1>0.943</td></tr></table>

# Expected Values/Reference Intervals

To determine a reference interval, serum samples from 367 subjects were acquired from 4 different sources representing 5 different geographic regions of the United States.

Sampling took place during the period of February - May 2013, representing a range of exposures to sunlight based on the geographic regions of sampling and to the transition of weather conditions from Winter to Spring to early Summer. Samples were acquired only from subjects in the range of 21-90 years of age, with no family or personal history of parathyroid disease, thyroid disease, calcium regulatory disease; and no personal history of kidney disease, gastrointestinal disease, liver disease, seizures, chronic disease, or bariatric surgery. Additionally, subjects were not taking any medications that might interfere with Vitamin D absorption. Lastly, subjects were restricted to $< 2 0 0 0$ IU/day of Vitamin D supplementation. The results indicated a reference interval of 13.7 - 57.3 $\mathfrak { n g } / \mathrm { m L }$ based on the non-parametric $2 . 5 ^ { 1 1 } - 9 7 . 5 ^ { 1 1 }$ percentiles.

<table><tr><td rowspan=1 colspan=2>Observed values</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>27.6 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>24.2 ng/mL</td></tr><tr><td rowspan=1 colspan=1>2.5th - 97.5thpercentile</td><td rowspan=1 colspan=1>13.7 - 57.3 ng/mL</td></tr></table>

# Method Comparison

Human serum samples were tested with the FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay and the obtained results were compared to the predicate method. A total of 137 samples ranging from 18.6 to $1 3 2 . 6 ~ \mathrm { \ n g / m L }$ were tested in both assays. The FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay correlated well with the predicate method with correlation coefficient (R) of 0.92, slope $= 0 . 9 7$ , and y-intercept $\mathbf { \tau } = - 4 . 6 \ \mathrm { n g / m L }$ .

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>0.97 (0.88 - 1.06)</td></tr><tr><td rowspan=1 colspan=1>y-intercept (95% CI)</td><td rowspan=1 colspan=1>-4.6 (-8.9 to -0.25)</td></tr><tr><td rowspan=1 colspan=1>R (95% CI)</td><td rowspan=1 colspan=1>0.92 (0.90 - 0.94)</td></tr><tr><td rowspan=1 colspan=1>Range of values</td><td rowspan=1 colspan=1>18.6 - 132.6 ng/mL</td></tr></table>

# SUMMARY

The information provided in this pre-market notification indicates that the FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay is substantially equivalent to the stated predicate device. The information further indicates that the FastPack $\textsuperscript { \textregistered }$ Vitamin D Immunoassay is safe and effective for its stated intended use.

Qualigen, Inc. C/O Michael Poirier 2042 Corte Del Nogal, Suite B CARLSBAD CA 92009

Re: K123983 Trade/Device Name: FastPack® Vitamin D Immunoassay FastPack® Vitamin D Calibrator Kit Fastpack® Vitamin D Control Kit FastPack® Vitamin D Method Verification Kit Regulation Number: 21 CFR 862.1825 Regulation Name: Vitamin D test system Regulatory Class: II Product Code: MRG, JIT, JJX Dated: May 31, 2013 Received: June 3, 2013

Dear Mr. Poirier:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (2 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml 15809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Enclosure

# Indications for Use

510(k) Number (if known): k123983

Device Name: Device Name:

FastPack Vitamin D Immunoassay FastPack Vitamin D Calibrator Kit FastPack® Vitamin D Control Kit FastPack® Vitamin D Method Verification Kit

Indications for Use:

FastPack® Vitamin D Immunoassay is intended for the quantitative determination of total 25-hydroxyvitamin D and other hydroxylated metabolites in human serum and plasma. The assay is to be used as an aid in the assessment of vitamin D sufficiency in adults. The FastPack® Vitamin D Immunoassay is intended for use with the FastPack® Analyzer.

FastPack® Vitamin D Calibrator Kit is used for calibrating the quantitative FastPack Vitamin D Immunoassay on the FastPack® Analyzer.

FastPack Vitamin D Control Kit is used for quality control of the FastPack® Vitamin D Immunoassay on the FastPack® Analyzer.

FastPack® Vitamin D Method Verification Kit is used in the quantitative verification of calibration and assay range of the quantitative FastPack® Vitamin D Immunoassay on the FastPack $\otimes$ Analyzer.

Prescription Use √ (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)